• B.A. at Ohio Wesleyan University
• M.D. at University of Rochester School of Medicine and Dentistry

Clips:

Showing Clips 1 through 8 of 8.  - Show Home

Show Home Page

Celebrex, Naproxen Won't Prevent Mental Decline Contrary to prior studies, a new trial shows that daily use of two popular pain-relieving drugs, Celebrex and naproxen, does not prevent cognitive decline in people with a family history of Alzheimer's disease. WUSTL neurology professor John Morris, who is director of WUSTL's Alzheimer's Disease Research Center and a member of the medical and scientific advisory council for the Alzheimer's Association, comments. References: May 12, 2008 — Celebrex, Naproxen Won't Prevent Mental Decline in the U.S. News & World Report and 9 others.

Dementia Diagnosis May Relieve Patients Doctors often hesitate to tell patients they likely suffer from Alzheimer's disease or another form of dementia, fearing the news will overwhelm them. Not only did the diagnosis not increase anxiety or depression among patients and their caregivers, but most were relieved to have symptoms explained and a way to find help. But a WUSTL medical study suggests physicians need not worry. Researchers amd WUSTL psychology professor Brian Carpenter and neurology proessor John Morris comment. The study, which appears in the March issue of the Journal of the American Geriatrics Society, gauged depression and anxiety two days before and two days after an evaluation and diagnosis. References: March 12, 2008 — Dementia Diagnosis May Relieve Patients in the Associated Press and 110 others.

Diabetes, obesity can increase your Alzheimer's risk School of Medicine's John Morris talks about Alzheimer's disease risk factors. November is National Alzheimer's Disease month. CNN medical correspondent Judy Fortin talked about the illness with John Morris, director of WUSTL's Alzheimer's Disease Research Center. He said besides old age, diabetes and obesity are also risk factors for developing Alzheimer's. References: Nov. 6, 2006 — Diabetes, obesity can increase your Alzheimer's risk in the CNN.com

Diagnosis: Dementia May Follow Higher Weight Loss in Aging Neurologist John Morris discusses the links between weight loss and Alzheimer's. Weight loss in people over 65 can be the result of normal aging, but new research suggests that it may also be an early indicator of Alzheimer's disease and other forms of dementia. WUSTL neurology professor and senior author John Morris comments on the study that appears in the September issue of Archives of Neurology. References: Sept. 19, 2006 — Diagnosis: Dementia May Follow Higher Weight Loss in Aging in the The New York Times

Clues to the mind robber Though still preliminary, the findings of a study which used a drug commonly used to treat rheumatoid arthritis add to a growing list of approaches that scientists are taking to uncover the biological roots of Alzheimer's and hit the disease where it hurts. Trials of a vaccine designed to clear the brain of amyloid were halted by Elan Pharmaceuticals in 2002, because 18 of 300 participants developed serious brain inflammation. But scientists continue to work on more selective vaccines that could help the body fight amyloid without harming surrounding tissue, says Dr. John C. Morris, director of the Alzheimer's Disease Research Center at Washington University in St. Louis. References: June 19, 2006 — Clues to the mind robber in the Los Angeles Times

Alzheimer's researchers land prestigious award WUSTL's John Morris is one of four scientists who received an award from MetLife Foundation for making key contributions to the understanding and treatment of Alzheimer's disease. References: Feb. 3, 2005 — Alzheimer's researchers land prestigious award in the Pittsburgh Post-Gazette and 2 others.

Drugs for Alzheimer's agitation often ineffective, study says Many antidepressants commonly used to calm the agitation, delusions and other behavioral problems associated with advanced Alzheimer's disease don't work well, a study reports. These drugs were designed for younger patients and not for older Alzheimer's patients. WUSTL Alzheimer's expert John Morris comments. References: Feb. 2, 2005 — Drugs for Alzheimer's agitation often ineffective, study says in the USA Today Feb. 2, 2005 — Alzheimer's Troubling Behaviors Hard to Treat in the Forbes.com and 3 others.

Alzheimer's drugs may deserve more time Alzheimer's medicine may be useful beyond just a few months In a shift that could affect one of the most agonizing decisions in Alzheimer's treatment — just how long to keep a patient on medication — several new studies suggest that the drugs may be effective for far longer, and have a wider range of benefits, than previously believed. John Morris, director of the School of Medicine's Alzheimer's Disease Research Center, comments. References: Sept. 7, 2004 — Alzheimer's drugs may deserve more time in the Wall Street Journal

Showing Clips 1 through 8 of 8.  - Show Home

Show Home Page

John Morris

Professor Morris' research involves clinicopathological studies of aging and dementia with a focus on early-stage Alzheimer disease. He is author or co-author of over 180 peer-reviewed journal articles and 50 chapters and reviews. He edited the Handbook of Dementing Illnesses. Professor Morris is Editor-in-Chief of Alzheimer's Disease and Associated Disorders and serves on the editorial board of The Neurologist. He is a Director of the National Alzheimer's Association, and a member of the Association's Medical and Scientific Advisory Council. He completed a term (1996-2000) as a member and chair of the Neuroscience of Aging Review Committee for the National Institute of Aging, Bethesda, Maryland. He serves on many scientific and community advisory boards and is a member or Fellow of numerous professional societies, including the American Academy of Neurology, the American Neurological Association, the American Geriatrics Society, and the Society for Neuroscience. He has received many honors, including the Distinguished Achievement Citation from his alma mater, Ohio Wesleyan University (2000), the Lifetime Achievement Award from the Alzheimer's Association (2004), the 2004 MetLife Foundation Award for Medical Research, and the 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology.